echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The third batch of key points of depth analysis: some enterprises may be disqualified from qualifying.

    The third batch of key points of depth analysis: some enterprises may be disqualified from qualifying.

    • Last Update: 2020-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Author . . . Code thousands of calls to start out, July 29, the third batch of volume procurement program officially issued, will be a few happy several sad, as well as "soul cut price" or will come again.
    not much to say, this time, the author on the open-door, directly on the important key provisions of this batch of national mining analysis and interpretation, for the reader's reference.
    01: Among other filing requirements, "1. The declaring enterprise shall ensure that the demand for the agreed quantity of drugs selected in the supply area is met within the procurement cycle" and "3. The declaring enterprise shall comply with the Patent Law, the Anti-Unfair Competition Law and other relevant laws and regulations, and bear the corresponding legal responsibilities" Analysis: The national drug collection documents are different from the local pilot procurement documents, and shall not set the threshold for production capacity or the weight of scores, without the comprehensive scoring method.
    three batches of national drug collection, the characteristics of these procurement documents may be used by some local pilot.
    The patent law and the anti-unfair competition law, which are ready-made and relatively perfect, are the supervision tools, which reflect the importance attached to the construction of the rule of law in the industry, even small and medium-sized enterprises, if they do not study the applicable law, the risk is passive.
    02: "2.2 Requirements for declaring enterprises: the declared varieties in the first two years of this drug centralized procurement activities, there is no provincial (including) or above drug supervision and administration department quality inspection failure (wherein generic drug non-conformity refers to through the State Drug Administration generic drug quality and efficacy consistency evaluation of non-conformity after listing)" analysis: This requirement is actually very strict.
    requirement that "there is no non-conformity within the first two years of the procurement activity" is likely to disqualifie some companies from being shortlisted (the specific list has not yet been counted) or to avoid participation simply for fear of exposure (there is currently no mandatory participation).
    that each of the selected companies will supply more than one province, the risk is very high.
    03:2.5 After declaring the election of enterprises, the purchase and sale agreement shall be signed in accordance with the requirements of each locality.
    2.6 In case of national policy adjustment or force majeilance in the performance of the agreement, which directly affects the implementation of the agreement, the parties to the purchase and sale agreement shall negotiate and resolve the "16.1 local in the joint procurement office issued the notice of the selection, in accordance with the local selected drugs and their selected prices in the provincial drug centralized procurement platform To complete the work of hanging up the network, according to the requirements of the organization signed the purchase and sale agreement and implement "analysis: in order to ensure the fair and efficient follow-up landing work of collection, it is recommended that consideration should be given to the introduction of a unified layout purchase and sale agreement with the use of national drug collection and collection, so that all places can share the general provisions, add special provisions, strengthen the purchase and sale agreement signed and implemented by the unified centralized record management.
    correspondingly, the adjustment situation encountered by the selected drugs, the consultation situation and the results should also be included in the supervision.
    04: "11.3 with the same variety declaration enterprises "unit available price" the same, according to the following rules in turn determined: (1) in 2019 the number of provincial supply areas of enterprises priority (based on local reporting data) ;(2) in 2019 in all areas of large sales of enterprises priority, multiple specifications of varieties, sales volume calculation (in places) (based on the data) ;(3) Analysis: Priority here is consistent with the previous description of the enterprise priority (which is based on the approval date of the State Drug Administration) ;(4) for enterprises producing API-produced products (limited to the same legal person as the API and preparation manufacturers) through or through the state Drug Administration's evaluation of generic drug quality and efficacy consistency.
    continues to emphasize "locally delivered data", from which the quantity differences and quality implications of the past year can be seen.
    , it will also expose the data differences and quality implications of the coming year.
    annual statistics and reports of the agreed amount of procurement, is a continuous closed loop, deliberately underestimated or overestimated will be in the horizontal, vertical comparison will be evident.
    To jump out of the data level, we can see from the order: First, the national collection respect for the historical development achievements of enterprises, and even encourage enterprises to open up more territory, and second, the pharmaceutical industry between excess and shortage to master the balance, API and preparation capacity of enterprises at least in the national collection is not the main advantage.
    will be subject to stricter regulation.
    05:2.1 In the same variety declaration enterprise, the head of the enterprise is the same person or different enterprises with direct holding and management relationship, shall not participate in the declaration of the same variety at the same time", "11.4 declaration of different enterprises of the same variety, if the head of the enterprise is the same person or there is a direct holding, management relationship, then the enterprise only "unit available price" the lowest and live in the finalist enterprise non-final qualification" analysis: these two provisions have some contradictions.
    "No such situation" was made clear in the previous article, and the 2st said "in case of such a situation".
    the risks that will prevail in the next article are still there.
    Assuming that there are enterprises drilling holes, lining up to be found easy to cause three disputes: First, the pro-front dismissal out of a few armor, affecting the normal participation in the enterprise's quotation strategy; 06:"13.1 It is proposed that the selected enterprises will enter the confirmation procedure of the supply area uniformly.
    the first-in-the-way enterprise to select 1 region in the supply area.
    After the priority selection is completed, from the first-in-place enterprise, all the selected enterprises in order to alternately confirm the remaining areas, each selected enterprise each time 1 region, repeat the above-mentioned process, until all regions selected to confirm.
    13.2 The enterprise to be selected should confirm the supply area in conjunction with the capacity of the enterprise, the choice must be confirmed, not abstained, otherwise it is considered to give up the qualification of the proposed selection, by other selected enterprises in order to confirm the supply area "analysis: following the above analysis, if there is no direct control, management relationship between enterprises, but there is still a situation of attack alliance, instant communication, will affect the normal confirmation process of the supply area.
    Extreme situation is: after the last round of selected enterprises in order to alternately confirm the region, Enterprise A felt that the results did not meet expectations, Enterprise B to the current round of selection of the region announced abstaining, accordingly, B enterprise in the previous round of selection of the region also lapsed, the program restart, Enterprise A regained the opportunity to choose.
    07:14. In the public announcement of the results of the proposed election, "after publicity, if the enterprise to be selected is disqualified from the selection, from the other selected enterprises of the variety to determine the replacement of the supply enterprise" analysis: the situation appearing in the last article should not be greater than the situation in this article.
    to be selected enterprises to be disqualified from selection, from other selected enterprises to determine the specific principles and practices of replacement, to be clarified.
    suggested that it would be more appropriate to draw lots on a par or random level.
    08:"Declaring enterprises, selected enterprises, distribution enterprises, if the following acts, the relevant departments determined that the serious circumstances will be included in the "violation list": 17.2 to provide prescription rebates or other commercial bribes, illegal promotional activities.
    17.12 In the sampling or flight inspection found that the selected enterprise seriously violated the commitments made in the declaration materials.
    " 18.1 declared enterprise is included in the "violation list", the enterprise's declaration qualification is cancelled;
    , depending on the serious circumstances, disqualifies the above-mentioned enterprises or varieties from participating in centralized drug procurement activities in various places within 2 years from the date of inclusion in the "violation list".
    18.2 If a distribution enterprise is included in the "violation list", it shall be disqualified from distribution of the enterprise and shall participate in the distribution qualification of centralized drug procurement in various places within 2 years from the date of the "violation list": even with the policy support of the purchase with volume, the enterprise is still prone to such habitual errors.
    law enforcement standards vary from place to place and may make the same mistakes face different judgments.
    A number of provisions of article 18 emphasize the seriousness and seriousness of the "violation list", i.e., once on the "violation list", it means that "an enterprise or variety cannot participate in the centralized procurement of medicines in various places within two years" and "distribution enterprises cannot participate in the distribution qualification of centralized procurement of drugs in various places within two years", reminding law enforcement to be strict.
    next, around the first year agreed purchase volume to talk about some views: First, 4 or more houses selected, get the agreed purchase volume of 80%.
    the results are happy, enterprises in the selection of areas, first of all will be based on their previous operating layout.
    In addition to looking at objective indicators, the unfamiliar provinces also take into account three elements: first, the extension of their own promotion programs, such as: this product drives the other product;
    is a home election, to get all over the country agreed to purchase 50% of the volume.
    , the procurement cycle is, in principle, only one year.
    if next year or a home election, or the lowest 50% decline, year after year is stopped a knife, for enterprises is unsustainable.
    methods are two: first, the market follow-up competition naturally solves the matter of 1 home selection, and second, in the follow-up national collection of different varieties of different reduction requirements.
    our view is that loneliness is "shameful" and that you are not an orphan.
    third is a number of defeats, they should get the agreed purchase volume of X%.
    X is unknown and falling.
    recommendation: allow the selected enterprises, varieties to complete the purchase and sale agreement volume, and strive for other hospital usage when continuing to reduce prices, do not increase prices on the line.
    Benefits are: First, to help the joint procurement office early to find the next collection of price reduction space, so as not to temporarily intend to plate;
    third, to solve only interference with 80% of the drug price is not complete.
    summary: the organization of drug belt procurement, is the lead in health insurance, medical reform in doing.
    or defeat in the bidding campaign is a reality that enterprises have to adapt to.
    if there is no strong, updated industrial progress support, with volume procurement has become a "sourceless water, rootless wood."
    the future, adhere to the protection of the winning, winning enterprises, varieties of legitimate interests of competition, will be more and more attention by the industry.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.